Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Viktrup

Showing results (101-110 of 111) with videos related to

Pageof 12
Sort By:
Journal of the Neurological Sciences|February 26, 2022
Neurological safety of subcutaneous tanezumab versus NSAID in patients with osteoarthritisMark T Brown, Paola Sandroni, Phillip A Low, et al.
Arthritis Care & Research|February 3, 2023
Reliability of Wearable Sensors for Assessing Gait and Chair Stand Function at Home in People With Knee OsteoarthritisMichael J Rose, Tuhina Neogi, Brian Friscia, et al.
Clinical Pharmacology and Therapeutics|January 9, 2023
Predicting Treatment Responses in Patients With Osteoarthritis: Results From Two Phase III Tanezumab Randomized Clinical TrialsLuana Colloca, Robert H Dworkin, John T Farrar, et al.
European Journal of Pain (London, England)|March 17, 2021
Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?Francis Berenbaum, Richard Langford, Serge Perrot, et al.
BMC Urology|January 29, 2008
Duloxetine versus placebo for the treatment of women with stress predominant urinary incontinence in Taiwan: a double-blind, randomized, placebo-controlled trialAlex Tong-Long Lin, Mou-Jong Sun, Hui-Lung Tai, et al.
Arthritis Research & Therapy|March 30, 2022
Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled studyTuhina Neogi, David J Hunter, Melvin Churchill, et al.
Pain|May 27, 2020
Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safetyJohn D Markman, Robert B Bolash, Timothy E McAlindon, et al.
Osteoarthritis Imaging|February 12, 2024
Inter-Reader Consistency and Exclusionary Findings During Radiographic Screening for Phase 3 Trials of Tanezumab in Patients With OsteoarthritisAli Guermazi, Frank W Roemer, Andrew J Kompel, et al.
Osteoarthritis and Cartilage|August 31, 2023
Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumabJohn A Carrino, Timothy E McAlindon, Tom J Schnitzer, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 4, 2021
Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized TrialMarc C Hochberg, John A Carrino, Thomas J Schnitzer, et al.
Pageof 12

Showing results (101-110 of 111) with videos related to

Sort By:
Pageof 12
Journal of the Neurological Sciences|February 26, 2022
Neurological safety of subcutaneous tanezumab versus NSAID in patients with osteoarthritisMark T Brown, Paola Sandroni, Phillip A Low, et al.
Arthritis Care & Research|February 3, 2023
Reliability of Wearable Sensors for Assessing Gait and Chair Stand Function at Home in People With Knee OsteoarthritisMichael J Rose, Tuhina Neogi, Brian Friscia, et al.
Clinical Pharmacology and Therapeutics|January 9, 2023
Predicting Treatment Responses in Patients With Osteoarthritis: Results From Two Phase III Tanezumab Randomized Clinical TrialsLuana Colloca, Robert H Dworkin, John T Farrar, et al.
European Journal of Pain (London, England)|March 17, 2021
Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?Francis Berenbaum, Richard Langford, Serge Perrot, et al.
BMC Urology|January 29, 2008
Duloxetine versus placebo for the treatment of women with stress predominant urinary incontinence in Taiwan: a double-blind, randomized, placebo-controlled trialAlex Tong-Long Lin, Mou-Jong Sun, Hui-Lung Tai, et al.
Arthritis Research & Therapy|March 30, 2022
Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled studyTuhina Neogi, David J Hunter, Melvin Churchill, et al.
Pain|May 27, 2020
Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safetyJohn D Markman, Robert B Bolash, Timothy E McAlindon, et al.
Osteoarthritis Imaging|February 12, 2024
Inter-Reader Consistency and Exclusionary Findings During Radiographic Screening for Phase 3 Trials of Tanezumab in Patients With OsteoarthritisAli Guermazi, Frank W Roemer, Andrew J Kompel, et al.
Osteoarthritis and Cartilage|August 31, 2023
Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumabJohn A Carrino, Timothy E McAlindon, Tom J Schnitzer, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 4, 2021
Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized TrialMarc C Hochberg, John A Carrino, Thomas J Schnitzer, et al.
Pageof 12